Catheter Precision SEC Filings

Catheter Precision filed an 8-K to attach a legal opinion supporting its Form S-3 prospectus supplement and to announce that its LockeT surgical vessel closing device received regulatory approval in Great Britain. The press release highlights potential benefits of LockeT for patient comfort, faster recovery and increased clinical throughput, but also contains extensive forward-looking cautionary language. The company discloses material weaknesses in internal control, a history of losses, the need to raise additional funds to continue operations, and multiple operational and market risks including competition, reimbursement, supply-chain and regulatory challenges.

Catheter Precision, Inc. implemented a 1-for-19 reverse stock split of its common stock after stockholder authorization, effective at 12:01 a.m. ET on August 15, 2025. The company combined every 19 issued shares into one share and reduced issued and outstanding common shares from approximately 23,327,516 to approximately 1,227,764. The common stock continues to trade under the symbol VTAK on the NYSE American on a split-adjusted basis and received a new CUSIP number.

Authorized capital remains unchanged at 10 million preferred and 60 million common shares. Proportionate adjustments were made to outstanding stock options, warrants, conversion prices and shares available under incentive plans. Fractional shares will not be issued; holders entitled to fractions will receive cash pro rata from aggregated fractional-share sales, net of customary fees.

Armistice Capital, LLC and Steven Boyd report collective beneficial ownership of 1,120,635 shares of Catheter Precision, Inc. common stock, representing 4.99% of the class. The filing states the Reporting Persons hold shared voting and dispositive power over these shares and have no sole voting or dispositive power. Armistice is the investment manager of the Master Fund, which directly holds the shares, and the Master Fund disclaims beneficial ownership by virtue of the investment management agreement. The Reporting Persons certify the holdings are in the ordinary course of business and not for the purpose of changing or influencing control.

James Joseph Caruso, a director of Catheter Precision, Inc. (VTAK), reported an option award on 08/12/2025. The filing shows an acquisition of 50,000 stock options with an exercise price of $0.18. The options are exercisable beginning 08/12/2025 and reference an 08/12/2035 date in the derivative table, with the filing stating the options vest one-third per year beginning on the first anniversary of the grant. After this transaction Caruso beneficially owns the 50,000 underlying shares directly. The form is signed 08/14/2025.

Catheter Precision, Inc. (VTAK) reported an insider transaction in which a company director was granted 50,000 stock options with an exercise price of $0.18. The options were granted on the reported transaction date and vest one-third each year beginning on the first anniversary of the grant. The options are exercisable through the expiration date in 2035, and the reporting person holds 50,000 underlying shares post-transaction.

This disclosure is a routine director equity award that creates long-term option-based compensation and the right to acquire 50,000 shares at the stated strike price subject to the vesting schedule.

David A. Jenkins, Executive Chairman of the Board of Catheter Precision, Inc. (VTAK), was granted 500,000 stock option awards on 08/12/2025. The options have an exercise price of $0.18 per share, an exercisable date listed as 08/12/2025 and an expiration date of 08/12/2035. The filing shows 500,000 underlying shares of common stock beneficially owned following the transaction, held directly. The options vest at 20% per year beginning on the first anniversary of the grant date, according to the explanation in the filing.

Catheter Precision, Inc. (VTAK) reported accelerating product sales and continued investment in new technologies while also recording material operating losses and liquidity strain. Product revenue totaled $355 thousand for the six months ended June 30, 2025, up from $175 thousand a year earlier, with U.S. sales of $308 thousand in the period. The company incurred a six-month net loss of $9.5 million and used $4.6 million of cash in operating activities.

Balance sheet items highlight short-term pressure: cash and cash equivalents were $0.8 million, working capital showed a $2.6 million deficit, and accumulated deficit reached $301.5 million. Material financing and corporate actions in 2025 included a May PIPE that generated $1.5 million in cash (and two convertible notes received as consideration), an ATM program that produced $1.7 million gross through June 30, 2025, formation of subsidiaries Cardionomix and KardioNav, acquisition of CPNS System assets, and an April 2025 U.S. patent for LockeT. Management discloses substantial doubt about the company’s ability to continue as a going concern and plans to seek additional financing.